Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 14/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3393270 | 0.85 | NR1H4 (0.51) | NR1H4KDM4EALDH1A1HPGDTSHR | |
| SCHEMBL3360536 | 0.85 | TP53 (0.40) | NR1H4KDM4EALDH1A1HPGDTSHR | |
| SCHEMBL3363076 | 0.85 | MAPT (0.48) | NR1H4KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL3393907 | 0.85 | TP53 (0.45) | NR1H4RAB9ANPC1KDM4EALDH1A1 | |
| SCHEMBL3394856 | 0.81 | GAA (0.39) | NR1H4KDM4EALDH1A1HPGDTSHR | |
| SCHEMBL3396264 | 0.77 | CRHR1 (0.38) | NR1H4ALDH1A1TP53GAA | |
| SCHEMBL3391218 | 0.71 | MAPT (0.45) | KDM4EALDH1A1HSD17B10TP53GAA | |
| SCHEMBL1692237 | 0.70 | NR1H4 (0.60) | NR1H4RAB9ANPC1KDM4EALDH1A1 | |
| SCHEMBL3359454 | 0.70 | NR1H4 (0.39) | NR1H4ALDH1A1TP53GAA | |
| SCHEMBL3392155 | 0.70 | TRPA1 (0.39) | RAB9ANPC1HPGDTP53GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150239905-A1 | IMIDAZOPYRIDINE COMPOUNDS | BIOVITRUM AB (PUBL) (SE) | 2015-08-27 | — | — | US | disclosed |
| EP-2376490-B1 | IMIDAZOPYRIDINE COMPOUNDS | PROXIMAGEN LTD (GB) | 2013-01-23 | — | — | EP | disclosed |
| WO-2010064020-A1 | IMIDAZOPYRIDINE COMPOUNDS | PROXIMAGEN LTD. (GB) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239905-A1 | IMIDAZOPYRIDINE COMPOUNDS | SSB, MIF, IDO1 | NR1H4 3133/4885RAB9A 3798/4885NPC1 1153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.